A Study of the Effect of SYN-010 on Subjects With IBS-C

Theriva Biologics, Inc.63 enrolled

Overview

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)

This is a Phase 2, randomized, multi-center, multi-dose study. Sixty subjects with irritable bowel syndrome with constipation who are between the ages of 18 and 65, inclusive, will be enrolled. The entire duration of the study may be up to 43 days (from Screening to the post end-of-study \[EOS\] visit telephone call).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions

SYN-010 21 mgDRUG

SYN-010 42 mgDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must have IBS-C and have a positive breath CH4 test result (\> 10 ppm) at Screening. * Subject must meet the modified Rome III criteria for IBS-C. * Subject must have an average abdominal pain intensity score of ≥ 3 (scale 0-10) reported at Screening and Baseline. * Subject must have an average of fewer than 3 complete spontaneous bowel movement (CSBMs) per week. * Subject must agree to refrain from making any lifestyle changes that may affect IBS-C symptoms from the time of Screening to the end of the study. Exclusion Criteria: * Subject has taken IBS treatments (prescription or over-the-counter), proton pump inhibitors, laxatives, antibiotics. * Subject currently has any structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility, or any unexplained and clinically significant symptoms such as lower GI bleeding, rectal bleeding, heme-positive stool, iron-deficiency anemia, weight loss, or systemic signs of infection. * Subject has been diagnosed with or has a family history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or any other form of familial colorectal cancer. * Subject reports loose (mushy) or watery stools (Bristol Stool Form Scale \[BSFS\] score of 6 or 7).

Locations (1)

Unnamed facility

Miami, Florida, United States

Outcomes

Primary Outcomes

Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.